1. Home
  2. AGIO vs SEI Comparison

AGIO vs SEI Comparison

Compare AGIO & SEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • SEI
  • Stock Information
  • Founded
  • AGIO 2007
  • SEI 2014
  • Country
  • AGIO United States
  • SEI United States
  • Employees
  • AGIO N/A
  • SEI N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • SEI
  • Sector
  • AGIO Health Care
  • SEI
  • Exchange
  • AGIO Nasdaq
  • SEI NYSE
  • Market Cap
  • AGIO 1.4B
  • SEI 1.2B
  • IPO Year
  • AGIO 2013
  • SEI 2017
  • Fundamental
  • Price
  • AGIO $39.05
  • SEI $31.40
  • Analyst Decision
  • AGIO Buy
  • SEI Strong Buy
  • Analyst Count
  • AGIO 6
  • SEI 8
  • Target Price
  • AGIO $58.60
  • SEI $43.71
  • AVG Volume (30 Days)
  • AGIO 602.7K
  • SEI 1.3M
  • Earning Date
  • AGIO 07-31-2025
  • SEI 07-23-2025
  • Dividend Yield
  • AGIO N/A
  • SEI 1.54%
  • EPS Growth
  • AGIO N/A
  • SEI N/A
  • EPS
  • AGIO 11.45
  • SEI 0.50
  • Revenue
  • AGIO $37,035,000.00
  • SEI $371,533,000.00
  • Revenue This Year
  • AGIO $22.30
  • SEI $65.83
  • Revenue Next Year
  • AGIO $219.19
  • SEI $35.50
  • P/E Ratio
  • AGIO $3.45
  • SEI $61.95
  • Revenue Growth
  • AGIO 25.96
  • SEI 33.59
  • 52 Week Low
  • AGIO $23.42
  • SEI $10.96
  • 52 Week High
  • AGIO $62.58
  • SEI $39.03
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 70.00
  • SEI N/A
  • Support Level
  • AGIO $34.60
  • SEI N/A
  • Resistance Level
  • AGIO $40.06
  • SEI N/A
  • Average True Range (ATR)
  • AGIO 1.49
  • SEI 0.00
  • MACD
  • AGIO 0.43
  • SEI 0.00
  • Stochastic Oscillator
  • AGIO 86.59
  • SEI 0.00

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About SEI SOLARIS ENERGY INFRASTRUCTURE INC

Solaris Energy Infrastructure Inc provides services in the oil and gas industry. Its solutions are Solaris software suite, Fluid management system, Automated control systems, Field services, Last mile management, Wet sand solutions, Power Solutions, and Integrated wellsite solution. Its segment include Solaris Power Solutions and Solaris Logistics Solutions. It derives maximum revenue from Solaris Logistics Solutions segment.

Share on Social Networks: